Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Nabumetone 750 Mg
Generic Name
Nabumetone
Active Ingredient
NabumetoneCategory
Nonsteroidal Anti-inflammatory Drug [EPC]
Variants
1
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 750 mg/1 | TABLET, FILM COATED | ORAL | 79739-7077 |
Detailed information about Nabumetone 750 Mg
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Nabumetone 750 Mg, you must consult a qualified healthcare professional.
Nabumetone is a nonsteroidal anti-inflammatory drug (NSAID) used to manage pain and inflammation in osteoarthritis and rheumatoid arthritis. As a prodrug, it offers a unique pharmacological profile compared to other traditional NSAIDs.
The dosage of Nabumetone must be individualized based on the patient's clinical response, the severity of the condition, and their overall health profile. Healthcare providers always aim to use the lowest effective dose for the shortest duration possible to minimize the risk of cardiovascular and gastrointestinal side effects.
Nabumetone is generally not recommended for use in children. Its safety and effectiveness in pediatric populations (under the age of 18) have not been established. Healthcare providers typically opt for NSAIDs with more robust pediatric data, such as ibuprofen or naproxen, for conditions like juvenile idiopathic arthritis.
Because the metabolites of Nabumetone are excreted by the kidneys, patients with impaired renal function require close monitoring. For those with moderate renal insufficiency (creatinine clearance of 30 to 49 mL/min), a reduction in the starting dose is often necessary. In cases of severe renal impairment (creatinine clearance less than 30 mL/min), the use of Nabumetone is generally avoided unless the benefits clearly outweigh the risks, as the active metabolite can accumulate to toxic levels.
Since Nabumetone is a prodrug that requires the liver for activation, severe hepatic impairment can interfere with its efficacy. While specific dose adjustment scales (like Child-Pugh) are not strictly defined for Nabumetone, clinicians typically exercise extreme caution and may choose an alternative medication that does not require extensive hepatic bioactivation.
Older adults (aged 65 and over) are at a higher risk for NSAID-related complications, including gastrointestinal bleeding and kidney dysfunction. Healthcare providers often start elderly patients at the lower end of the dosing range (e.g., 500 mg to 750 mg daily) and monitor them frequently for signs of adverse effects.
If you miss a dose of Nabumetone, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular schedule. Never 'double up' or take two doses at once to make up for a missed one, as this increases the risk of side effects.
Signs of a Nabumetone overdose may include severe lethargy, drowsiness, nausea, vomiting, and epigastric (upper abdominal) pain. In rare cases, gastrointestinal bleeding, hypertension (high blood pressure), acute renal failure, respiratory depression, and coma may occur.
In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately. Treatment is typically supportive and symptomatic, as there is no specific antidote for Nabumetone. Because the active metabolite is highly protein-bound, hemodialysis is generally not effective in removing the drug from the body.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop the medication without medical guidance.
While Nabumetone is often better tolerated than some older NSAIDs, it can still cause a range of side effects. The most common issues involve the digestive system. Up to 15% of patients may experience:
These symptoms often appear within the first few weeks of treatment and may diminish as the body adjusts to the medication.
Between 1% and 9% of patients may experience the following:
Rare but serious reactions include:
> Warning: Stop taking Nabumetone and call your doctor immediately if you experience any of the following:
Prolonged use of Nabumetone increases the risk of cumulative damage to the organ systems. Chronic use is associated with an increased risk of developing peptic ulcers, even if no initial symptoms are present. Long-term NSAID therapy can also lead to 'analgesic nephropathy,' a form of chronic kidney disease caused by the long-term inhibition of renal prostaglandins. Additionally, chronic use may slightly elevate the risk of cardiovascular events, particularly in patients with pre-existing heart disease.
Like all prescription NSAIDs, Nabumetone carries the FDA's most serious 'Black Box' warning regarding two major risks:
Report any unusual symptoms or persistent side effects to your healthcare provider immediately to ensure your treatment remains safe and effective.
Nabumetone is a powerful medication that requires careful medical supervision. It is not a simple 'painkiller' and can affect multiple organ systems. Patients must be aware that the absence of symptoms (like stomach pain) does not guarantee that the drug is not causing internal damage, particularly to the stomach lining or kidneys.
Cardiovascular Thrombotic Events: Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years' duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, myocardial infarction, and stroke, which can be fatal. All NSAIDs, both COX-2 selective and nonselective, may have a similar risk. Patients with known CV disease or risk factors for CV disease may be at greater risk. To minimize the potential risk for an adverse CV event in patients treated with an NSAID, the lowest effective dose should be used for the shortest duration possible.
Gastrointestinal Bleeding, Ulceration, and Perforation: NSAIDs, including Nabumetone, cause an increased risk of serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the stomach, small intestine, or large intestine, which can be fatal. These events can occur at any time during use and without warning symptoms.
Because of the potential for 'silent' side effects, healthcare providers typically require regular laboratory monitoring for patients on long-term Nabumetone therapy:
Nabumetone may cause dizziness, drowsiness, or visual disturbances in some patients. You should not drive, operate heavy machinery, or perform dangerous activities until you know how this medication affects you.
Combining Nabumetone with alcohol significantly increases the risk of gastrointestinal bleeding and stomach ulcers. It is generally advised to avoid or strictly limit alcohol consumption while taking any NSAID.
Unlike some medications (such as corticosteroids or antidepressants), Nabumetone does not typically require a tapering schedule to prevent withdrawal. However, stopping the medication will likely result in the return of arthritis symptoms (pain and stiffness). Always consult your doctor before stopping the medication to discuss alternative pain management strategies.
> Important: Discuss all your medical conditions, especially heart, kidney, or liver problems, with your healthcare provider before starting Nabumetone.
Nabumetone does not typically interfere with common laboratory tests, but its effect on platelets may lead to a slightly prolonged bleeding time test. It may also cause false-positive results in some fecal occult blood tests if active GI bleeding is present.
Most interactions with Nabumetone occur through one of three mechanisms:
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete medication review is essential for safety.
Nabumetone must NEVER be used in the following circumstances:
In these situations, the use of Nabumetone requires a careful risk-benefit analysis by a healthcare provider:
There is a high degree of cross-sensitivity between Nabumetone and other NSAIDs. If a patient has had a severe reaction to ibuprofen, naproxen, or diclofenac, they are highly likely to react to Nabumetone. This includes respiratory reactions (bronchospasm) and skin reactions (hives). However, Nabumetone is chemically distinct from sulfonamides, so patients with 'sulfa' allergies can typically take Nabumetone safely, unlike celecoxib.
> Important: Your healthcare provider will evaluate your complete medical history, including any past reactions to pain medications, before prescribing Nabumetone.
Nabumetone use during pregnancy is complex and depends on the trimester:
Data on the excretion of Nabumetone's active metabolite (6-MNA) into human milk is limited. However, because 6-MNA has a long half-life and is highly protein-bound, it is expected to be present in breast milk. Because of the potential for serious adverse reactions in nursing infants from NSAIDs, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
As previously noted, Nabumetone is not FDA-approved for use in patients under 18 years of age. The safety profile, particularly regarding long-term growth and development, has not been established in children. For pediatric inflammatory conditions, clinicians typically use medications with established safety data in children, such as naproxen or ibuprofen.
Elderly patients (65 years and older) are at the highest risk for serious NSAID-related complications.
In patients with moderate renal impairment (CrCl 30-49 mL/min), the terminal half-life of 6-MNA may increase, and protein binding may decrease, leading to higher levels of 'free' (active) drug. Dose reductions are mandatory. In severe renal failure (CrCl < 30 mL/min), Nabumetone is generally not recommended.
In patients with compensated hepatic cirrhosis, the pharmacokinetics of 6-MNA are not significantly altered. However, because the liver is the site of bioactivation, any progression to liver failure would make the drug both ineffective and potentially more toxic due to impaired protein synthesis (less albumin for the drug to bind to).
> Important: Special populations require individualized medical assessment and more frequent monitoring by a healthcare professional.
Nabumetone is a non-acidic, nonsteroidal anti-inflammatory drug (NSAID) that acts as a prodrug. Upon ingestion, it undergoes extensive first-pass hepatic metabolism to form 6-methoxy-2-naphthylacetic acid (6-MNA). 6-MNA is the active moiety that inhibits the enzyme cyclooxygenase (COX). By inhibiting COX, the drug prevents the conversion of arachidonic acid into various prostaglandins (PGE2, PGI2) and thromboxanes.
Specifically, 6-MNA shows a higher degree of selectivity for the COX-2 isoform than for COX-1 at therapeutic concentrations. COX-2 is primarily responsible for the production of prostaglandins that mediate pain and inflammation in the joints. By sparing COX-1 to some extent, Nabumetone may cause less direct damage to the gastric mucosa, although systemic inhibition of prostaglandins still poses a risk for ulcers.
The onset of the anti-inflammatory effect usually occurs within one week of starting regular therapy, but it may take two weeks or more to achieve maximum therapeutic benefit. Unlike 'rescue' medications like short-acting ibuprofen, Nabumetone is designed for steady-state maintenance. The duration of effect is long, matching its 24-hour half-life, which supports once-daily dosing.
| Parameter | Value |
|---|---|
| Bioavailability | ~80% (as metabolites) |
| Protein Binding | >99% (primarily to albumin) |
| Half-life (6-MNA) | 22 to 30 hours |
| Tmax (6-MNA) | 9 to 12 hours |
| Metabolism | Hepatic (Prodrug to 6-MNA) |
| Excretion | Renal 80%, Fecal 10% |
Nabumetone is classified as a nonsteroidal anti-inflammatory drug (NSAID), specifically within the naphthylalkanone group. It is therapeutically related to other NSAIDs like naproxen and diclofenac but is pharmacologically unique due to its prodrug activation and non-acidic structure.
Common questions about Nabumetone 750 Mg
Nabumetone is a prescription nonsteroidal anti-inflammatory drug (NSAID) primarily used to treat the symptoms of osteoarthritis and rheumatoid arthritis. It works by reducing the production of prostaglandins, which are chemicals in the body that cause inflammation, swelling, and joint pain. Unlike some other NSAIDs, it is a 'prodrug,' meaning it only becomes active after being processed by the liver. Healthcare providers often choose it for long-term management because its effects last for a full 24 hours. It is not typically used for acute, short-term pain like a headache or toothache.
The most common side effects associated with Nabumetone are gastrointestinal in nature, including diarrhea, indigestion, abdominal pain, and nausea. Diarrhea is particularly common, affecting up to 14% of patients in clinical trials. Some people may also experience dizziness, headache, or swelling in the ankles and feet due to fluid retention. While many of these side effects are mild and resolve as the body adjusts to the medication, persistent symptoms should be discussed with a doctor. More serious but less common side effects include stomach ulcers, kidney issues, and increased blood pressure.
It is generally recommended that you avoid or strictly limit alcohol consumption while taking Nabumetone. Alcohol can irritate the stomach lining, and when combined with an NSAID, the risk of developing stomach ulcers or gastrointestinal bleeding increases significantly. Even moderate alcohol intake can exacerbate the blood-thinning effects of the medication. If you have a history of heavy alcohol use, you are at a much higher risk for liver and stomach complications. Always consult your healthcare provider about what level of alcohol consumption, if any, is safe for you.
Nabumetone is generally not recommended during pregnancy, especially during the third trimester. Taking Nabumetone after 30 weeks of pregnancy can cause serious heart and kidney problems in the developing fetus and may lead to complications during delivery, such as delayed labor or excessive bleeding. In the first and second trimesters, it should only be used if absolutely necessary and prescribed by a doctor who has weighed the risks. If you are planning to become pregnant or find out you are pregnant while taking Nabumetone, contact your healthcare provider immediately. There are often safer alternatives for pain management during pregnancy.
Nabumetone is not a fast-acting pain reliever; it is designed for the long-term management of chronic inflammation. Most patients begin to feel some relief within 3 to 7 days of starting the medication. However, it typically takes 2 weeks of consistent daily use to achieve the full therapeutic anti-inflammatory effect. Because it has a very long half-life, the drug builds up slowly in your system. If you do not feel an improvement after two weeks, your doctor may adjust your dosage or consider a different medication.
Yes, you can generally stop taking Nabumetone suddenly without experiencing physical withdrawal symptoms, as it is not an addictive or habit-forming medication. However, because Nabumetone is used to treat chronic conditions like arthritis, stopping the drug will likely cause your joint pain, stiffness, and swelling to return. It is always best to consult with your healthcare provider before discontinuing the medication. They can help you determine if your condition has improved enough to stop treatment or if you should transition to a different therapy.
If you miss a dose of Nabumetone, take it as soon as you remember. If it is nearly time for your next scheduled dose, skip the missed one and continue with your regular dosing schedule. Do not take two doses at the same time to 'catch up,' as this significantly increases your risk of stomach irritation and other side effects. Because Nabumetone stays in your system for a long time, missing a single dose is unlikely to cause an immediate return of severe pain. Maintaining a consistent daily schedule is the best way to ensure the medication works effectively.
Nabumetone can cause weight gain in some patients, but this is usually due to fluid retention (edema) rather than an increase in body fat. NSAIDs can cause the kidneys to retain more sodium and water, leading to swelling in the legs, ankles, and hands. If you notice a sudden, rapid weight gain (such as 3-5 pounds in a single week) or significant swelling, you should contact your doctor immediately. This could be a sign of a strain on your heart or kidneys, especially if you have pre-existing heart failure or high blood pressure.
Nabumetone can interact with several other medications, so it is vital to provide your doctor with a full list of what you take. It should not be taken with other NSAIDs (like aspirin or ibuprofen) or blood thinners (like warfarin) due to a high risk of bleeding. It can also interfere with blood pressure medications, lithium, and methotrexate. Even over-the-counter supplements like Ginkgo biloba can increase bleeding risks. Your healthcare provider will check for these interactions to ensure that Nabumetone is safe to combine with your current medication regimen.
Yes, Nabumetone is widely available as a generic medication in both 500 mg and 750 mg tablet strengths. The generic version is much less expensive than the original brand-name drug, Relafen, which is no longer commonly marketed in the U.S. Generic Nabumetone is required by the FDA to have the same active ingredient, strength, dosage form, and route of administration as the brand-name version. It is also required to be bioequivalent, meaning it works in the body in the same way and provides the same clinical benefit.
Other drugs with the same active ingredient (Nabumetone)